Skip to content

Clinical efficacy of concentrated growth factor versus sodium hyaluronate in the treatment of knee osteoarthritis: an open-label randomized controlled study

Clinical efficacy of concentrated growth factor versus sodium hyaluronate in the treatment of knee osteoarthritis: an open-label randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124071
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-01-14
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

contrast group:Sodium hyaluronate was injected into the knee cavity
intervention group:Concentrated growth factor was injected into the knee cavity

Sponsors

Yancheng First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis of knee arthritis by standardized radiological assessment (i.e., standing anteroposteric and lateral X-ray views); 2. Kellgren-Lawrence Scale is I, II, or III, Visual Analogue Scale (VAS) pain score Moderate pain (>4); 3. Age >18; 4. Subject understands and signs informed consent.

Exclusion criteria

Exclusion criteria: 1. Kellgren-Lawrence Rating Scale IV; 2. Female patients who are pregnant, nursing or trying to become pregnant; 3. BMI>30; 4. Previous history of knee fracture surgery, knee instability and other diseases; 5. 3 History of intraregional injection or periarticular invasive treatment and surgery within the past month; 6. Autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis; 7. Past or present malignant tumors; 8. Suffers from neuropathic joint disease, hepatitis B and other diseases; 9. Suffering from HIV and other immunodeficiency diseases; 10. Suffering from cerebral hemorrhage, severe pneumonia, multiple organ dysfunction and other serious diseases; 11. Severe anemia; 12. Past or present mental or psychological illness; 13. Active infection in other parts of the body; 14. Patients with diabetes whose FBG exceeds 8mmol/L and is still poorly controlled after taking medicine; 15. Currently using anticoagulant drugs; 16. Patients who cannot follow up;

Design outcomes

Primary

MeasureTime frame
Western Ontario and McMaster Universities Arthritis Index, WOMAC;

Secondary

MeasureTime frame
visual analogue scale, VAS ;International Knee Documentation Committee;

Countries

China

Contacts

Public ContactSun Guan

Yancheng First People's Hospital

ycs1ykjc@163.com+86 515 66696892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026